Third in-stent restenosis in sirolimus eluting stents: predictors of the next restenosis
- PMID: 21452246
- DOI: 10.1002/ccd.22916
Third in-stent restenosis in sirolimus eluting stents: predictors of the next restenosis
Abstract
Objectives: We evaluated the predictive factors for recurrent restenosis lesions treated on two previous occasions with sirolimus-eluting stents (SES).
Background: Angiography data related to recurrent SES restenosis have not been reported.
Methods: Binary restenosis was observed in 66 patients with 78 lesions from a total of 1,393 patients with 1,965 lesions who received follow-up angiography after SES implantation. We enrolled 55 patients with 67 lesions who underwent revascularization using another SES with a second follow-up coronary angiography. These restenotic lesions were divided into two groups based on the presence or absence of recurrent restenosis: no recurrent restenosis group (n = 56) and recurrent restenosis group (n = 11). The coronary angiography data during first and second SES implantation were compared between the groups.
Results: Minimal lumen diameter (MLD) was smaller before first and second percutaneous coronary interventions (PCI) with SES implantation in the recurrent restenotic group compared with no recurrent restenosis group (first PCI, 0.28 ± 0.19 mm vs. 0.54 ± 0.42 mm, P = 0.040; second PCI, 0.44 ± 0.36 mm vs. 0.69 ± 0.39 mm, P = 0.036, respectively). Acute stent recoil after second SES implantation was significantly greater in the recurrent restenosis group compared with no recurrent restenosis group (0.08 ± 0.17 mm vs. 0.20 ± 0.22 mm, P = 0.049, respectively). Multivariate analysis showed preprocedural MLD at first PCI and acute stent recoil at second PCI as independent predictors of recurrent restenosis.
Conclusions: Preprocedural smaller MLD at first PCI and acute stent recoil at second PCI are predictors of recurrent restenosis treated on two previous occasions with SES.
Copyright © 2011 Wiley Periodicals, Inc.
Similar articles
-
Late restenosis following sirolimus-eluting stent implantation.JACC Cardiovasc Interv. 2011 Jan;4(1):123-8. doi: 10.1016/j.jcin.2010.09.013. JACC Cardiovasc Interv. 2011. PMID: 21251639
-
Repeated sirolimus-eluting stent implantation to treat sirolimus-eluting stent and bare-metal stent restenosis.Circ J. 2010 Nov;74(11):2329-33. doi: 10.1253/circj.cj-10-0210. Epub 2010 Sep 28. Circ J. 2010. PMID: 20890050
-
A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents.EuroIntervention. 2010 Feb;5(7):841-6. doi: 10.4244/eijv5i7a141. EuroIntervention. 2010. PMID: 20142201
-
Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment.Int J Cardiol. 2017 Mar 1;230:91-96. doi: 10.1016/j.ijcard.2016.12.073. Epub 2016 Dec 22. Int J Cardiol. 2017. PMID: 28038808 Review.
-
Diabetes and restenosis.Cardiovasc Diabetol. 2022 Feb 14;21(1):23. doi: 10.1186/s12933-022-01460-5. Cardiovasc Diabetol. 2022. PMID: 35164744 Free PMC article. Review.
Cited by
-
Analysis of the incidence and influencing factors associated with binary restenosis of target lesions after drug-coated balloon angioplasty for patients with in-stent restenosis.BMC Cardiovasc Disord. 2022 Nov 20;22(1):493. doi: 10.1186/s12872-022-02923-z. BMC Cardiovasc Disord. 2022. PMID: 36404303 Free PMC article. Clinical Trial.
-
Derivation and validation of the ISAR score to predict the risk of repeat percutaneous coronary intervention for recurrent drug-eluting stent restenosis.EuroIntervention. 2023 Apr 3;18(16):e1328-e1338. doi: 10.4244/EIJ-D-22-00860. EuroIntervention. 2023. PMID: 36785947 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous